Related Experiment Videos
Liposomal amphotericin B in neonates with invasive candidiasis
H al Arishi1, H H Frayha, A Kalloghlian
1Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Abstract:
Liposomal amphotericin B L-Amp B, a novel formulation of Amp B, is effective for the treatment of invasive fungal infections in children and adults and is associated with less toxicity than the conventional preparation. Data on the use of L-Amp B in neonates is scarce. We describe the clinical course of two premature infants who were treated with L-Amp B (one infant had candidemia, and the other had candidemia and meningitis), and provide a summary of previously published experience on this topic. L-Amp B may be an option for therapy of invasive candidiasis in neonates who are at high risk of nephrotoxicity and other amphotericin-related reactions, but clinical trials are necessary to document its safety and efficacy in this age group.
Insights
Liposomal amphotericin B (L-Amp B) shows promise for treating invasive fungal infections in premature infants. Further clinical trials are needed to confirm its safety and effectiveness in this vulnerable population.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections pose a significant risk to neonates.
- Conventional amphotericin B formulations can cause severe toxicity, particularly nephrotoxicity.
- Liposomal amphotericin B (L-Amp B) offers a potentially safer alternative for treating fungal infections.
Observation:
- This study reports on two premature infants treated with L-Amp B for invasive candidiasis.
- One infant experienced candidemia, while the other had both candidemia and meningitis.
- A review of existing literature on L-Amp B use in neonates was also conducted.
Findings:
- L-Amp B was used to treat invasive fungal infections in two premature infants.
- The cases suggest L-Amp B may be a viable therapeutic option for neonatal invasive candidiasis.
- Existing data on L-Amp B in neonates is limited.
Implications:
- L-Amp B may be a suitable alternative for neonates at high risk of amphotericin B-related toxicities.
- Clinical trials are essential to establish the definitive safety and efficacy of L-Amp B in neonates.
- This research highlights the need for further investigation into L-Amp B's role in neonatal antifungal therapy.